Yahoo
NYSEArca - Nasdaq Real Time Price USD

AdvisorShares Psychedelics ETF (PSIL)

26.33 -0.47 (-1.75%)
At close: August 26 at 4:00:00 PM EDT
26.20 -0.11 (-0.42%)
Pre-Market: 7:00:03 AM EDT
Trade PSIL on Coinbase
Chart Range Bar
Loading chart for PSIL
  • Previous Close 26.80
  • Open 26.56
  • Bid 24.73 x 30000
  • Ask 27.89 x 30000
  • Day's Range 26.29 - 27.02
  • 52 Week Range 15.64 - 27.02
  • Volume 23,173
  • Avg. Volume 42,677
  • Net Assets 48.53M
  • NAV 26.39
  • PE Ratio (TTM) --
  • Yield 7.30%
  • YTD Daily Total Return 56.09%
  • Beta (5Y Monthly) 0.56
  • Expense Ratio (net) 1.00%

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.

AdvisorShares

Fund Family

Miscellaneous Sector

Fund Category

48.53M

Net Assets

2021-09-15

Inception Date

Performance Overview

View More

Trailing returns as of 8/25/2026. Category is Miscellaneous Sector.

YTD Return

PSIL
56.09%
Category
--

1-Year Return

PSIL
73.16%
Category
--

3-Year Return

PSIL
22.93%
Category
--

People Also Watch

Holdings

View More

Top 10 Holdings (70.03% of Total Assets)

Symbol Company % Assets
AtaiBeckley Inc. 14.15%
DFTX 12.05%
COMPASS Pathways plc 9.83%
HELP.NE 5.47%
RLMD 5.32%
GH Research PLC 4.82%
NRXP 4.74%
NBIX 4.66%
ANRO 4.55%
DRUG.CN 4.44%

Sector Weightings

Research Reports

View More
  • Rating increased to a HOLD

    Schrodinger Inc/United States has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.

    Rating
    Price Target
  • Johnson & Johnson Earnings: A Steady 2025 and Improving 2026 Warrant a FVE Increase

    Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

    Rating
    Price Target
  • Pfizer Earnings: In-Line Quarter Despite Covid Product Weakness as Metsera Drama Intensifies

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
  • Pfizer: Metsera Acquisition Puts Firm Back in Contention in Potential $200 Billion GLP-1 Market

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: